Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research: ADA 81st Symposium
Mental Disorders Complicate the Treatment of Patients with Diabetes
Letter from the Editor
Many patients that wear a continuous glucose sensor also use pump therapy. This means at any time they have 2 injection sites in use on their body, and those sites are more often than not in the abdominal area. If the patient is a new user it is not a problem, but more seasoned users will seemingly run out of places to insert the devices. If you look at the patient on a Dexcom CGM and a T-Slim pump, they are inserting an average of 13 times a month. Although we tell patients that they only have to move a few centimeters away from a previously used site, that does not often happen. If the patient is using either a Freestyle Libre or an Omnipod they have the opportunity to use their upper arms as well.
The question is, could they use the Dexcom G6 on their upper arm, like the Libre, and get accurate readings? Our intern, Torré Anderson, II, Doctor of Pharmacy Candidate, Florida A&M College of Pharmacy, found a great study from the ADA Scientific Symposium that reviewed the use of the G6 on the upper arm. Although it is not indicated to be used on the upper arm, the results of the study may give you the info you need to discuss with your patients.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
TOP STORIES — Diabetes News and Research
Diet and exercise coaches are the future of preventing T2D in patients with overweight or obesity.
Individuals with mental health disorders have an increased risk for type 2 diabetes and premature death; modifiable risk factors affected by antipsychotics are obesity, insulin resistance, diabetes, and dyslipidemia.
Alternative site placement of continuous glucose monitor device is assessed in the hospital setting.
Did You Know? Noninvasive Glucose Monitors Will Change Future of Diabetes Management
When noninvasive glucose monitors become available, it will change how patients manage their blood sugars. We have CGMs, but they are expensive, and insurance will not cover the cost for those not using insulin. More than 65 noninvasive and minimally invasive bloodless glucose monitoring products are available or in development, and the devices may become critical digital tools for people with diabetes.
There are three types of noninvasive glucose monitors (NGM) in development. Noninvasive optical glucose monitoring is a device in which radiation is passed through the avascular region of the body. A noninvasive fluid sampling includes devices in which body fluid is collected without puncturing the skin. Finally, minimally invasive glucose monitoring includes devices in which a sensor provides glucose concentration over an extended period with a single insertion into the skin with minimal pain. Researchers reviewed 65 products: 28 noninvasive optical products, six noninvasive fluid-sampling devices, and 31 minimally invasive glucose monitoring products. None of the noninvasive optical and fluid-sampling products have received FDA approval, and four received CE clearance. The overall strategy is to provide a glucose-sensing technology that does not require a needle to puncture the skin and simultaneously reduces waste, increases convenience, and saves money.
For bloodless noninvasive glucose monitoring to continue improving, superior analytic performance, robust algorithm development, traceability testing for glucose-containing matrices besides blood, and appreciation for the clinical value of interstitial fluid glucose measurements are needed, according to the researchers. However, it is only a matter of time before a company can put all the pieces together. Journal of Diabetes Science and Technology, June 13, 2021
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:
Torré Anderson, II, Fourth Year Doctor of Pharmacy Candidate, Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health
Ashley Ball, PharmD Candidate, LECOM-School of Pharmacy
Macrina Ghali, PharmD Candidate 2021, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences
Kornelia Ilias, Creighton University | School of Pharmacy and Health Professions Doctor of Pharmacy Candidate Class of 2022
Alan Martinez, PharmD Candidate, University of South Florida Taneja College of Pharmacy
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com